Q1 Earnings Forecast for NTLA Issued By Leerink Partnrs

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Intellia Therapeutics in a research report issued on Thursday, February 27th. Leerink Partnrs analyst M. Foroohar expects that the company will post earnings of ($1.39) per share for the quarter. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. Leerink Partnrs also issued estimates for Intellia Therapeutics’ Q2 2025 earnings at ($1.17) EPS and FY2026 earnings at ($4.82) EPS.

Several other equities analysts have also recently issued reports on NTLA. William Blair restated a “neutral” rating and issued a $14.00 price target on shares of Intellia Therapeutics in a research report on Monday, November 18th. Truist Financial cut their price target on Intellia Therapeutics from $90.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday. BMO Capital Markets dropped their price objective on shares of Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating on the stock in a research note on Friday, January 10th. Canaccord Genuity Group restated a “buy” rating and issued a $90.00 price target on shares of Intellia Therapeutics in a research note on Tuesday, November 19th. Finally, StockNews.com raised Intellia Therapeutics to a “sell” rating in a report on Monday. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $38.00.

Intellia Therapeutics Stock Performance

Shares of NASDAQ:NTLA opened at $9.10 on Monday. Intellia Therapeutics has a one year low of $8.30 and a one year high of $32.42. The stock has a market capitalization of $942.00 million, a price-to-earnings ratio of -1.67 and a beta of 1.97. The company has a 50-day simple moving average of $10.74 and a 200-day simple moving average of $15.36.

Insider Activity

In related news, CEO John M. Leonard sold 26,807 shares of the company’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the sale, the chief executive officer now directly owns 941,115 shares of the company’s stock, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 29,000 shares of company stock valued at $352,551 in the last 90 days. 3.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Intellia Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Regeneron Pharmaceuticals Inc. acquired a new stake in Intellia Therapeutics during the 4th quarter valued at approximately $43,177,000. Voloridge Investment Management LLC increased its stake in shares of Intellia Therapeutics by 226.8% in the fourth quarter. Voloridge Investment Management LLC now owns 1,526,994 shares of the company’s stock worth $17,805,000 after buying an additional 1,059,751 shares during the last quarter. Contrarius Group Holdings Ltd bought a new position in Intellia Therapeutics during the 4th quarter valued at $11,798,000. Two Sigma Advisers LP increased its position in shares of Intellia Therapeutics by 94.5% in the 4th quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company’s stock worth $23,300,000 after purchasing an additional 970,700 shares during the last quarter. Finally, Two Sigma Investments LP raised its stake in shares of Intellia Therapeutics by 88.1% in the 4th quarter. Two Sigma Investments LP now owns 1,843,743 shares of the company’s stock valued at $21,498,000 after purchasing an additional 863,363 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.